Clinical Characteristics and Outcomes of Pediatric B-Cell Acute Lymphoblastic Leukemia Harboring TP53 Mutations: A Single-Center Retrospective Study - PubMed
6 hours ago
- #TP53 mutation
- #Pediatric B-ALL
- #Prognosis
- This retrospective study analyzed 32 pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with TP53 mutations.
- The median age at onset was 7 years, with a 1.46:1 male-to-female ratio, and many patients had fusion genes (47%) and abnormal karyotypes (65%).
- All patients achieved complete remission after induction therapy, but relapse occurred in 3 patients, leading to poor outcomes despite salvage therapies like CAR-T and HSCT.
- The 3-year event-free survival rate was 92%, with no significant differences in survival based on mutation type or site.
- TP53 mutations occur in about 3% of pediatric B-ALL cases, often with complex genetics, and while initial response is good, relapse is associated with a poor prognosis and limited treatment efficacy.